Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

NCT ID: NCT02965560

Last Updated: 2018-06-06

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 350 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2016-10-10
• Study Completion Date: 2018-06-01

Brief Summary

Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).

Conditions

Acute-On-Chronic Liver Failure; Cirrhosis and Chronic Liver Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

HC,CHB,AD,ACLF

HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.

plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.

Intervention Type: DIAGNOSTIC_TEST

Interventions

plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of acute-on-chronic liver failure according to Asian-Pacific Association for the Study of the Liver (APASL) diagnostic criteria

Exclusion Criteria

• Hepatocellular carcinoma(HCC)
• Portal vein thrombosis
• Pregnancy
• Human immunodeficiency virus (HIV)
• Patients who had received immunomodulator,or cytotoxic/immunosuppressive therapy within at least the preceding 12 months

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

First Affiliated Hospital of Zhejiang University

OTHER

Sponsor Role: lead

Responsible Party

Haihong Zhu

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

References

Wang Y, Wu F, Chen C, Xu L, Lin W, Huang C, Yang Y, Wu S, Qi J, Cao H, Li G, Hong M, Zhu H. Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure. BMC Gastroenterol. 2021 Nov 17;21(1):429. doi: 10.1186/s12876-021-02006-x.

Reference Type: DERIVED

PMID: 34789156 (View on PubMed)

Other Identifiers

tclouds

Identifier Type: -

Identifier Source: org_study_id